How does 42Z's PB Ratio compare to its peers?

42Z is expensive based on its Price-To-Book Ratio (6.1x) compared to the peer average (3x).

How does 42Z's PB Ratio compare vs other companies in the DE Biotechs Industry?

42Z is expensive based on its Price-To-Book Ratio (6.1x) compared to the European Biotechs industry average (2.4x).

What is 42Z's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 42Z's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 42Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 42Z's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Revolution Medicines (DB:42Z) - Stock Price, News & Analysis

42Z Stock Overview

A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. More details

42Z fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 81.37% per year

Analysts in good agreement that stock price will rise by 25.9%

Risk Analysis

Makes less than USD$1m in revenue ($742K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Significant insider selling over the past 3 months

Shareholders have been diluted in the past year

Revolution Medicines, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€827.2m

Sartorius

XTRA:SRT3

€13.4b

Heidelberg Pharma

XTRA:HPHA

€103.9m

Price History & Performance

Summary of all time highs, changes and price drops for Revolution Medicines
Historical stock prices
Current Share Price	US$53.50
52 Week High	US$56.50
52 Week Low	US$19.50
Beta	1.4
11 Month Change	23.27%
3 Month Change	36.48%
1 Year Change	174.36%
33 Year Change	124.79%
5 Year Change	n/a
Change since IPO	77.74%

Recent updates

Shareholder Returns

	42Z	DE Biotechs	DE Market
7D	1.9%	-0.7%	0.2%
1Y	174.4%	-17.2%	8.5%

Return vs Industry: 42Z exceeded the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: 42Z exceeded the German Market which returned 8.5% over the past year.

Price Volatility

Is 42Z's price volatile compared to industry and market?
42Z volatility
42Z Average Weekly Movement	5.6%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: 42Z has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 42Z's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2014	490	Mark Goldsmith	www.revmed.com

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets.

Revolution Medicines, Inc. Fundamentals Summary

How do Revolution Medicines's earnings and revenue compare to its market cap?
42Z fundamental statistics
Market cap	€9.17b
Earnings (TTM)	-€544.55m
Revenue (TTM)	€712.54k

Over9,999x

P/S Ratio

-16.8x

P/E Ratio

Is 42Z overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
42Z income statement (TTM)
Revenue	US$742.00k
Cost of Revenue	US$426.14m
Gross Profit	-US$425.40m
Other Expenses	US$141.66m
Earnings	-US$567.06m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-3.37
Gross Margin	-57,331.27%
Net Profit Margin	-76,423.32%
Debt/Equity Ratio	0%

How did 42Z perform over the long term?

See historical performance and comparison

42Z Stock Overview

Rewards

Risk Analysis

Revolution Medicines, Inc. Competitors

XTRA:BIO3

€1.4b

XTRA:FYB

€827.2m

XTRA:SRT3

€13.4b

XTRA:HPHA

€103.9m

Price History & Performance

Recent News & Updates

CEO, President & Chairman recently sold €507k worth of stock

Revolution Medicines, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Now 22% undervalued

Now 20% undervalued

New major risk - Revenue size

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Recent updates

CEO, President & Chairman recently sold €507k worth of stock

Revolution Medicines, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Now 22% undervalued

Now 20% undervalued

New major risk - Revenue size

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Revolution Medicines, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New major risk - Revenue and earnings growth

Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024

Revolution Medicines, Inc. Announces Publication Demonstrating Robust Anti-Tumor Activity of Ras(On) Inhibitors in Preclinical Models of Refractory Kras-Mutated Non-Small Cell Lung Cancer

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)

Revolution Medicines, Inc. to Report Q1, 2024 Results on May 08, 2024

Revolution Medicines, Inc., Annual General Meeting, Jun 20, 2024

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $124.825544 million.

Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024

Full year 2023 earnings released: US$3.86 loss per share (vs US$3.09 loss in FY 2022)

New major risk - Revenue and earnings growth

Revolution Medicines, Inc. to Report Q4, 2023 Results on Feb 26, 2024

New major risk - Shareholder dilution

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Third quarter 2023 earnings released: US$0.99 loss per share (vs US$0.87 loss in 3Q 2022)

Revolution Medicines, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Revolution Medicines, Inc. Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

New major risk - Revenue and earnings growth

New major risk - Share price stability

Revolution Medicines, Inc. Provides Pipeline Updates

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.82 loss in 2Q 2022)

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2023

Revolution Medicines, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Revolution Medicines, Inc.(NasdaqGS:RVMD) dropped from Russell Small Cap Comp Value Index

First quarter 2023 earnings released: US$0.72 loss per share (vs US$0.78 loss in 1Q 2022)

Revolution Medicines, Inc. Announces Executives Appointment

Full year 2022 earnings released: US$3.09 loss per share (vs US$2.57 loss in FY 2021)

Revolution Medicines, Inc. Announces Publication Describing Design and Synthesis of RMC-5552

Revolution Medicines, Inc. to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

Revolution Medicines, Inc. Updates Earnings Guidance for 2022

Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.72 loss in 3Q 2021)

Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2022

Revolution Medicines, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

Revolution Medicines, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.60 loss in 2Q 2021)

Revolution Medicines, Inc. Provides Earnings Guidance for the Year 2022

Revolution Medicines, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Revolution Medicines, Inc. Appoints Lorence Kim to Board of Directors

Revolution Medicines, Inc. Elects Sushil Patel to its Board of Directors

Revolution Medicines, Inc. Appoints Sushil Patel, Ph.D. as Director

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.53 loss in 1Q 2021)

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2022

Revolution Medicines, Inc. to Report Q1, 2022 Results on May 09, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Revolution Medicines, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2021

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference